Device Trial Radar · NCT04760002
DANish Patients With Atrial Fibrillation and Sleep Apnea Prevalence by Night Owl
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Jan 25, 2021
Primary completion
Jan 1, 2023
Study completion Jan 1, 2023
Sponsor
- Lead sponsor
- Herlev and Gentofte HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sygekassernes Helsefond
- First posted
- Feb 18, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 90 years
Summary
As written by the sponsor on the registry.
A project of the feasibility of using NightOwl to detect the prevalence of obstructive sleep apnea (OSA) in patients with atrial fibrillation (AF). The long-term aim is to use the device to screen for OSA in a randomized clinical trial in AF patients undergoing ablation and/or a randomized trial of AF patients undergoing cardioversion.
Conditions
- Obstructive Sleep Apnea
Interventions
NightOwlDevice
The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of obstructive sleep apnea in atrial fibrillation patientsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Herlev-Gentofte Hospital
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.